What I didn't like was:

   -hearing that they did some more 'ATM' here in the 1st 1 qtr of 2023 (more share dilution)  Target price has already taken a hit due to the share count running up from 11 Mil to it was 25 Mil.

   -just a 'blurb' on what they have done to prepare for an expansion into the oncology sector (ie, nothing on what will have to take place, potential timeline (hoping they have done things on this front, just not talking about it)

   

 Optimistic:   on the Class 1 pathway.  Depends on whether or not an inspection is reqd that could delay things.

 

  To close, what looked like it had a great potential in terms of a reward to patient shareholders has lost some of its 'luster' thanks to the ATMs.  Hopefully the 1st leg of this journey is reaching a conclusion.   (and wish they were WEEKLY options to mess around with. Monthlys are too darn long when things arent 'predictable')